{
    "2019-01-08": [
        [
            {
                "time": "",
                "original_text": "医药生物行业月报: 结构调整下多数公司进入价值区间, 创新是最确定的方向",
                "features": {
                    "keywords": [
                        "医药生物",
                        "结构调整",
                        "价值区间",
                        "创新"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业周报: 关注商誉减值及解禁风险, 不确定的市场中寻找确定性",
                "features": {
                    "keywords": [
                        "医药",
                        "商誉减值",
                        "解禁风险",
                        "确定性"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "2019年1月医药行业投资策略: “轻药重医”为正道, 首推医疗器械板块",
                "features": {
                    "keywords": [
                        "医药",
                        "投资策略",
                        "轻药重医",
                        "医疗器械"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "医疗器械"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "联讯医药行业周观点: 广州gpo首批谈判目录再次绷紧“降价”神经, 继续躲在避风港还是选择卧倒“弹坑”中",
                "features": {
                    "keywords": [
                        "医药",
                        "广州gpo",
                        "降价",
                        "避风港",
                        "弹坑"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}